PPARG and neoplasm: As a consequence, PPARγ has been regarded as a possible target for anti-cancer therapy and TZDs have been used in clinical trials for the treatment of tumours involving different organs and tissues, such as prostate (Hisatake et al, 2000; Mueller et al, 2000), colon (Kulke et al, 2002), breast (Burstein et al, 2003), lung and adipose tissue (Demetri et al, 1999; Tsubouchi et al, 2000; Debrock et al, 2003).